Moleculin Biotech closes $9.3 million public offering with Roth Capital as placement agent

Moleculin Biotech, Inc. entered into a placement agency agreement with Roth Capital Partners, LLC on July 31, 2026 for a public offering of 12,376,667 shares of common stock, or pre-funded warrants in lieu thereof, along with Series I Common Stock Purchase Warrants to purchase up to an aggregate of 37,130,001 shares of common stock.¹ Each unit of stock (or pre-funded warrant) and accompanying common warrant was priced at $0.75 per share.¹

The pre-funded warrants carry a nominal exercise price of $0.001 per share, and expire when exercised in full.¹ The common warrants are exercisable into one share of common stock at $0.75 per share and expire on the five-year anniversary of the initial exercise date.¹

The offering closed on August 3, 2026.¹ Gross proceeds were approximately $9.3 million, before deducting placement agent fees and other offering expenses.¹ The company said it plans to use net proceeds to advance Annamycin through clinical development and for working capital.¹

Under the purchase agreement, Moleculin agreed to a 45-day restriction on issuing or announcing new securities after closing¹, along with a longer restriction on variable rate transactions until 180 days after closing, subject to exceptions, with at-the-market sales permitted starting on day 46.¹

Roth Capital Partners will receive a cash fee equal to 6.5% of gross proceeds¹ plus expense reimbursement not to exceed $100,000 in the aggregate.¹ Maxim Group LLC served as financial advisor and received a fee of 1.0% of the aggregate gross proceeds of the offering.¹ Company directors and officers also signed lock-up agreements restricting sales of common stock for 60 days following the closing date.¹